San Antonio Breast Cancer Symposium (SABCS): December 2022
Dana-Farber faculty led and participated in spotlight sessions, debates, poster presentations, lectures, and conducted sessions covering clinical, translational and basic research at this year's SABCS 2022.
Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.
Ann Partridge, MD, MPH, led the study presented at the 2022 San Antonio Breast Cancer Symposium which showed most women participating in the study went on to deliver healthy babies.
ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.